Emergent BioSolutions Highlights Strategic Engagements with European Partners to Supply Vital Emergency Medical Countermeasures

Demonstrating significant partnerships and global health leadership via support of the EU's stockpiles

Timed to the first in-country Health Emergency Preparedness and Response Authority (HERA) Information Day in Paris, France, Emergent recognizes HERA's commitment to strengthened dialogue between all the key stakeholders, private and public healthcare provider networks, pharmaceutical and medical manufacturing companies, emergency services, civil society organizations, and non-governmental organizations.

Today, Emergent has provided a comprehensive review of its 2023 strategic collaborations and engagements with key global partners delivering medical countermeasures. Throughout the last year, Emergent has been supporting the development of the EU's own emergency rescEU stockpiles, some of which are funded by HERA, supplying EU Member States with needed medical countermeasures, vaccines, and treatments, that respond to a range of chemical, biological, or nuclear (CBRN) threats.

"We stand at a critical juncture where global public health and preparedness have never been more vital. Our collaboration with international partners is paramount to enhancing global health security. We are proud to have played a pivotal role in advancing Europe's response capabilities," said Paul Williams, SVP and products business head at Emergent. "In the year ahead, Emergent will continue meeting the needs of our domestic and international partners to ensure they have access to the innovations that keep us healthy, prepared, and responsive to a range of public health threats."

The European Commission is making a groundbreaking effort to prevent and rapidly respond to cross-border health emergencies by facilitating the development, manufacturing, and distribution of medical countermeasures. The rescEU reserve coordination efforts include stockpiles of CBRN protective equipment, medicines, and treatments.

As a leader in the medical countermeasures space for 25 years, Emergent is honored to have successfully secured and executed contracts in 2023 that support European communities via the EU Civil Protection Mechanism and meet Europe's health needs and requirements, including:

• Signature of a contract with Johanniter's Competence Center EU Civil Protection and Disaster Assistance in Germany for the provision of Emergent's skin decontamination kit.
• Signature of a contract on Emergent's medical countermeasures products on behalf of rescEU.
  • Deliveries of the anthrax vaccine and botulism antitoxin started in 2023 and will continue in 2024.
• Supply of skin decontamination kit to the French Ministry of Health to support the rescEU reserve. Deliveries were made in 2023, completing the contract.

To learn more about Emergent's work and efforts as an essential partner in ensuring governments have the necessary medical countermeasures available in case of an emergency, you can view highlights from Emergent leaders speaking at Politico's EU Healthcare Summit in October 2023 here.